(ACAD) ACADIA Pharmaceuticals Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ACAD) ACADIA Pharmaceuticals Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This ACADIA Pharmaceuticals Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
DAYBUE, 2023 FDA approval
DAYBUE, ACADIA Pharmaceuticals Inc.'s trofinetide, won FDA approval in 2023 for Rett syndrome and became its newest commercial asset. In 2024, it generated about $395 million in net sales, showing strong launch momentum in a rare-disease market with a U.S. prevalence near 1 in 10,000 female births. That growth profile and strategic priority fit a Star in the BCG Matrix.
Rett syndrome, 2+ years
DAYBUE is approved for Rett syndrome in patients aged 2 years and older, and ACADIA Pharmaceuticals Inc. is still building the market from a very small treated base. Rett syndrome affects about 1 in 10,000 to 15,000 female births, so early share gains matter more than legacy scale. That makes this indication a Star in ACADIA Pharmaceuticals Inc.’s BCG Matrix.
First approved Rett therapy
DAYBUE is the first FDA-approved treatment for Rett syndrome, so ACADIA Pharmaceuticals Inc. has true first-mover advantage. That usually drives fast physician adoption and high visibility in a rare-disease market. In BCG terms, this is Star logic: strong growth potential plus a leading position.
Rare-disease launch, 2024-2025
DAYBUE’s Rett syndrome launch still looks like a Star: ACADIA Pharmaceuticals Inc. is in the early growth phase, with 2024-2025 sales still driven by new-patient starts, payer coverage, and repeat access rather than a mature base. That is classic high growth from a low base, not steady-state demand.
- First-in-class rare-disease launch
- Growth still shaped by payer access
- 2024-2025 demand is not mature
Pipeline-to-revenue bridge
DAYBUE is ACADIA Pharmaceuticals Inc.'s clearest pipeline-to-revenue bridge: the drug turned a development win into $378.3 million of 2024 net product revenue and helped lift total 2024 revenue to $960.8 million. That makes it the company’s main growth engine beyond NUPLAZID and the asset most worthy of heavy reinvestment.
As a Star in BCG terms, DAYBUE broadens ACADIA Pharmaceuticals Inc. beyond one marketed brand and gives management a second commercial platform to fund aggressively.
- 2024 DAYBUE revenue: $378.3 million
- 2024 total revenue: $960.8 million
- Key role: pipeline-to-revenue bridge
- BCG fit: Star, high-priority funding
DAYBUE Powers ACADIA’s Growth Surge
DAYBUE is ACADIA Pharmaceuticals Inc.'s Star: the first FDA-approved Rett syndrome therapy and the company's main growth engine. Net product revenue reached $378.3 million in 2024, with total revenue at $960.8 million, showing strong launch momentum from a small base. Its role is still expanding, so heavy reinvestment fits BCG Star logic.
| Metric | Value |
|---|---|
| DAYBUE FDA approval | 2023 |
| 2024 net product revenue | $378.3 million |
| 2024 total revenue | $960.8 million |
What is included in the product
Detailed Word Document
BCG Matrix for ACADIA Pharmaceuticals: spot Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
Clean ACADIA Pharmaceuticals BCG Matrix for fast quadrant analysis and clearer portfolio decisions
Reference Sources
ACADIA Pharmaceuticals Inc. reference sources provide a clear credibility trail that helps validate claims and speed confident decision-making.
Cash Cows
NUPLAZID, 2016 FDA approval
NUPLAZID, approved by the FDA in 2016 for hallucinations and delusions tied to Parkinson’s disease psychosis, is ACADIA Pharmaceuticals Inc.’s mature cash cow. It has a long commercial track record and still anchors the Company’s revenue base, with 2025 filings showing it remains the core product in the portfolio.
Only approved PDP therapy
NUPLAZID is the only FDA-approved medicine for Parkinson's disease psychosis, so ACADIA Pharmaceuticals Inc. holds a rare, protected niche. In 2025, that sole-approved status helped support durable demand and steady cash generation from a defined patient pool, which is the classic Cash Cow pattern.
Parkinson’s disease psychosis niche
Parkinson’s disease psychosis is a narrow niche: Parkinson’s affects about 1 million people in the U.S., and psychosis develops in up to 50% over the disease course. That makes demand specialized, but not fast-growing. With ACADIA Pharmaceuticals Inc.'s NUPLAZID already established, this is classic Cash Cow territory: mature specialty sales, high share, and limited new-patient growth.
Recurring branded sales
NUPLAZID is ACADIA Pharmaceuticals Inc.'s recurring branded seller, so each refill adds steady prescription revenue instead of one-time milestone income. That kind of base is what makes a Cash Cow: in FY2024, ACADIA Pharmaceuticals Inc. reported $824.0 million in total revenue, and that cash flow helps fund operations and R&D.
- Repeat prescriptions drive cash
- Lower risk than one-off deals
- Funds research and operations
R&D funding source
NUPLAZID is ACADIA Pharmaceuticals Inc.’s Cash Cow: its mature sales still help fund R&D and corporate overhead, so the company can back newer growth bets without relying only on outside capital.
That fits the classic biopharma Cash Cow role: a steady, approved product that throws off cash while ACADIA keeps investing in pipeline programs. One product can pay for the next one.
- NUPLAZID supports pipeline spend
- It helps cover fixed overhead
- It funds future growth drivers
NUPLAZID Powers ACADIA’s Recurring Revenue Engine
NUPLAZID is ACADIA Pharmaceuticals Inc.’s Cash Cow: in 2025, it remained the only FDA-approved treatment for Parkinson’s disease psychosis and the main source of recurring revenue.
That niche is slow-growing but durable, so refill demand can keep cash coming in while the Company funds R&D and overhead.
| Metric | 2025 |
|---|---|
| NUPLAZID status | Only FDA-approved PDP drug |
| Role | Cash Cow |
Preview Before You Purchase
ACADIA Pharmaceuticals Inc. Reference Sources
You’re previewing the exact ACADIA Pharmaceuticals Inc. BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted version—no demo content or hidden changes. Once purchased, it’s ready for immediate download and use in your analysis or presentation.
Dogs
No low-share brand
ACADIA Pharmaceuticals Inc. has no clear "Dog" in its core mix because it does not disclose a marketed product with both low share and low growth. In fiscal 2025, total revenue was about $864 million, led by NUPLAZID and DAYBUE, which kept the commercial base concentrated in two CNS brands. That means the BCG grid shows a focused portfolio, not a low-share drag.
No generic franchise
ACADIA Pharmaceuticals Inc. has no generic or commoditized branded franchise to classify as a true Dog. Its 2025 profile is still driven by specialty neuroscience and rare-disease products, led by NUPLAZID and DAYBUE, which are not low-margin legacy lines. That keeps the portfolio tied to targeted demand, not a declining cash-drain brand.
No divested legacy product
ACADIA Pharmaceuticals Inc. shows no clear divested legacy product in its FY2025 portfolio view; the company stayed focused on 2 core commercial assets, NUPLAZID and DAYBUE. That matters in a BCG Matrix because Dogs usually show up when older brands are left to fade, and ACADIA does not show that pattern. Instead, its 2025 mix points to active concentration, not a stranded legacy line.
No underperforming mature unit
ACADIA Pharmaceuticals Inc. has no disclosed unit that fits the Dog profile of weak growth and weak share. Its marketed assets, Nuplazid and Daybue, are either established leaders or growth products, so the Dog quadrant is effectively empty.
- No weak-share, low-growth unit disclosed
- Marketed assets remain strategic winners
- Dog quadrant is effectively empty
Portfolio concentration
ACADIA Pharmaceuticals Inc. stays tightly focused on CNS and rare-disease therapies, with 2025 revenue still driven mainly by NUPLAZID and DAYBUE. That concentration raises product-risk, but it also avoids the weak, scattered assets that usually land in Dogs. In BCG terms, the Dog bucket here looks minimal to none.
- Focused on two core franchises
- 2025 sales remain product-concentrated
- Low Dog exposure from portfolio sprawl
ACADIA’s FY2025: No Dog, Just Two Core Growth Brands
ACADIA Pharmaceuticals Inc. shows no clear Dog in FY2025. Revenue was about $864 million, led by NUPLAZID and DAYBUE, so the portfolio stayed concentrated in two active brands rather than a weak legacy asset.
| FY2025 Signal | Value |
|---|---|
| Revenue | about $864 million |
| Core brands | NUPLAZID, DAYBUE |
| Dog quadrant | effectively empty |
Question Marks
Pimavanserin, Alzheimer’s psychosis Phase 3
Pimavanserin is in Phase 3 for Alzheimer’s disease psychosis, a much bigger addressable pool than Parkinson’s psychosis: about 6.9 million U.S. adults 65+ live with Alzheimer’s disease, and psychosis can emerge in a large share of cases. If ACADIA Pharmaceuticals Inc. wins, this could extend beyond NUPLAZID’s narrower Parkinson’s use. For now, it is a high-upside, unproven growth bet.
Pimavanserin, schizophrenia Phase 3
Pimavanserin’s Phase 3 run in schizophrenia targets negative symptoms, a tough area that affects up to 60% of patients and has few approved options. Schizophrenia impacts about 24 million people worldwide, so the market is large, but this use case is still unproven. That makes it a classic Question Mark for ACADIA Pharmaceuticals Inc.
ACP-044, Phase 2 pain
ACP-044 is an oral non-opioid analgesic in Phase 2, so it sits in a huge pain market but still has no approved sales. Chronic pain affects about 51.6 million U.S. adults, which shows the scale of the prize. In BCG terms, that makes ACP-044 a Question Mark: high-growth potential, low current return, and clear dependence on successful clinical data.
ACP-044, chronic pain Phase 2
ACP-044's chronic pain readout keeps ACADIA Pharmaceuticals Inc. in Question Mark territory: chronic pain is a huge market, with about 51.6 million U.S. adults affected in 2021, but Phase 2 means clinical proof is still thin.
That makes the program high-upside but not yet de-risked, so the commercial case hinges on showing clear pain relief, tolerability, and dose fit versus crowded options.
- Large unmet need
- Phase 2 only
- Proof still limited
- Potentially sizable market
ACP-319, Phase 1 CNS
ACP-319 is a Phase 1 positive allosteric modulator of the muscarinic receptor, still too early to generate sales. ACADIA is testing it in 2 key CNS uses: schizophrenia and cognition in Alzheimer’s disease. In BCG terms, it is a Question Mark because it needs more capital and data before it can win share.
- Phase 1 asset
- 2 target indications
- High R&D spend risk
- Future growth, no revenue yet
ACADIA’s Big Bets: High-Upside, High-Risk Question Marks
ACADIA Pharmaceuticals Inc. has four clear Question Marks: pimavanserin in Alzheimer’s disease psychosis and schizophrenia, ACP-044 in chronic pain, and ACP-319 in early CNS work. Each sits in a large market, but none has proven commercial scale yet.
The upside is real: Alzheimer’s affects about 6.9 million U.S. adults 65+, schizophrenia about 24 million people worldwide, and chronic pain about 51.6 million U.S. adults. But Phase 1 to Phase 3 risk still makes cash flow uncertain.
| Program | Stage | BCG view |
|---|---|---|
| Pimavanserin AD psychosis | Phase 3 | Question Mark |
| ACP-044 chronic pain | Phase 2 | Question Mark |
| ACP-319 CNS | Phase 1 | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.